ClinicalTrials.gg
CompletedNCT07723365epidemiologyUpdated Jul 23, 2026

Epidemiological, Clinicopathological, and Surgical Characteristics of Eyelid Carcinomas

An observational study in Carcinomas (Including Squamous Cell and Adenocarcinoma), sponsored by Mohammed VI University Hospital. Completed at 1 site in Morocco. Per ClinicalTrials.gov, last updated 2026-07-23.

Primary conditionAdenocarcinomaRegistry: CarcinomaReclassifiedWhy we changed it
Registry
Carcinoma — the first condition term the registry derived for this study.
ClinicalTrials.gg
Adenocarcinoma
Why
  1. The study's listed conditions name Adenocarcinoma, a narrower term within Carcinoma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Mohammed VI University Hospital · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
20
Sex
All
01

Study summary

Twenty patients were included, comprising 11 women (55%) and 9 men (45%), with a mean age of 63.1 years. Chronic sun exposure was identified in 18 patients (90%). The lower eyelid was the most commonly affected site in 9 cases (45%). Basal cell carcinoma accounted for 15 tumors (75%), followed by squamous cell carcinoma in 5 cases (25%). Wide local excision with histopathological margin control was performed in all patients (20/20, 100%), and orbital exenteration was required in 1 case (5%). Reconstruction was achieved mainly using local flaps in 12 patients (60%). Ectropion occurred in 2 patients (10%). No local recurrence was observed during a mean follow-up of 22 months.

Read the detailed description

This retrospective study was conducted over a three-year period, from January 2023 to December 2025, and included 20 patients with eyelid carcinomas who underwent surgical treatment in the Department of Plastic and Reconstructive Surgery at Mohammed VI University Hospital. Demographic, clinical, histological, therapeutic, and outcome data were analyzed.

02

Conditions studied

  • Carcinomas (Including Squamous Cell and Adenocarcinoma)

Browse trials for

Keywords

  • carcinomas
  • epidemiologie
  • surgery
03

In context

Adenocarcinoma Reclassified

620 studies on the registry are indexed under Adenocarcinoma; 148 are open to participants now.

This study's enrollment of 20 is below the median of 182 across 98 observational studies indexed under Adenocarcinoma.

Browse Adenocarcinoma studies →

Lead sponsor

Mohammed VI University Hospital is the lead sponsor of 11 studies on the registry; 1 is open to participants now.

Compared within Adenocarcinoma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Carcinoma. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Twenty patients were included in the study: 11 women (55%) and 9 men (45%). The mean age at diagnosis was 63.1 ± 22.3 years (range, 16-90 years).

Regarding skin phototype, 5 patients (25%) had Fitzpatrick phototype II, 9 patients (45%) had phototype III, and 6 patients (30%) had phototype IV [4]. Most patients reported substantial lifetime sun exposure, often related to outdoor occupational activities such as farming or security work. Overall, chronic sun exposure was identified in 18 patients (90%).The remaining two patients (10%) had limited cumulative sun exposure due to their young age; however, they remained highly susceptible to UV radiation because of a history of xeroderma pigmentosum.

Actinic keratosis was noted in one patient (5%), a history of eyelid trauma in one patient (5%), and chronic tobacco use in two patients (10%), both of whom were male. Xeroderma pigmentosum was present in two patients (10%). No history of arsenic exposure or prior radiotherapy was documented in

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • all patient with carcinoma

Exclusion criteria

Exclusion Criteria:

  • no exclusion criteria
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
20 participants (actual)
Patient registry
No

Groups and cohorts

  • carcinomas

    patient with carcinomas

06

What researchers measure

Primary outcomes

  1. Eyelid carcinomas

    Time frame: from January 2023 to December 2025

07

Study locations

1 site
  • Oujda
    Oujda, 60000, Morocco
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07723365
Lead sponsor
Mohammed VI University Hospital
Responsible party
Younes Oujidi (Dr Elkadiri, Mohammed VI University Hospital) — Principal investigator
First posted
Jul 23, 2026
Start date
Jan 1, 2023
Primary completion
Jan 1, 2026
Completion
Jun 1, 2026
Last update
Jul 23, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion